Long-Term Use of Sorafenib May Cause Irreversible Pancreatic Atrophy
Two patients who had been using the drug sorafenib (Nexavar, Bayer/Onyx) over several years have developed pancreatic atrophy, the New England Journal of Medicine reports.
Sorafenib and Pancreatic Atrophy
- According to MedScape, sorafenib is an oral inhibitor of vascular endothelial growth factor (VEGF) and used to treat kidney and liver cancers.
- One researcher writes that long-term use of the drug “could cause cumulative, serious, and life-threatening late toxic effects.”
- One of the patients had been taking the drug for 2.5 years and the other for 3 years. A volumetric CT of their abdomens showed a 20% reduction in the volume of the pancreas in one patient and a 35% reduction in the other .
- The study has led to questions concerning the safety of VEGFs, if they can cause similar side effects and whether or not the benefit of the drug outweigh the risks.
Adverse Events Associated with Sorafenib
- 17,925 adverse events have been reported to DrugCite.com concerning sorafenib.
- The most common adverse event reported with sorafenib were epidermal and dermal conditions.
Other possible adverse events tide to sorafenib include:
- Palmar-plantar Erythrodysaesthesia Syndrome
- Trouble Breathing
- Liver Failure
Contact an Experienced Product Liability Attorney
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/ or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects from the use of defective medications or pharmaceuticals, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.